口服乙酰半胱氨酸与年龄相关性黄斑变性风险:一项回顾性队列研究
该研究基于台湾全民健康保险研究数据库的回顾性队列,纳入2003至2017年间22498例NAC使用者和138607例非使用者,经倾向评分匹配后每组各5234例。NAC使用者发生年龄相关性黄斑变性的风险显著低于非使用者(HR 0.19),干性和湿性亚型均观察到保护性关联,并呈剂量反应关系。
要点
- 倾向评分匹配后每组各5234例,NAC使用者AMD风险显著低于非使用者(HR 0.19,95%CI 0.14-0.26,P<0.001)。
- 干性AMD风险显著降低(HR 0.19,95%CI 0.14-0.26),湿性AMD风险亦降低(HR 0.31,95%CI 0.12-0.81)。
- 累积剂量越高,AMD和干性AMD风险降低越明显,呈剂量反应关系。
核心结论
- NAC使用与AMD风险显著降低相关,尤其是干性AMD。
- 作者认为这些发现支持进一步研究NAC作为AMD预防性治疗的有效性。
研究设计与样本
- 回顾性队列研究,使用台湾全民健康保险研究数据库。
- 2003至2017年间纳入22498例NAC使用者和138607例非使用者,倾向评分匹配前。
- 倾向评分匹配后每组各5234例,匹配后采用Cox比例风险回归模型估计结局的风险比(HR)。
- 按年龄和性别进行分层分析,并计算累积限定日剂量以评估NAC使用者中的剂量反应关系。
主要发现
- 倾向评分匹配后,NAC使用者AMD风险显著低于非使用者(HR 0.19,95%CI 0.14-0.26,P<0.001)。
- 干性AMD风险在NAC使用者中显著降低(HR 0.19,95%CI 0.14-0.26)。
- 湿性AMD风险在NAC使用者中显著降低(HR 0.31,95%CI 0.12-0.81)。
- 分层分析显示NAC使用者AMD风险降低在不同年龄和性别组中一致。
- 累积NAC剂量越高,AMD和干性AMD风险降低越明显,呈剂量反应关系;对≥60岁和≥70岁患者的敏感性分析进一步支持该关联,尤其是干性AMD。
关键数值与推荐
- NAC使用者AMD风险:HR 0.19(95%CI 0.14-0.26,P<0.001),对照为非NAC使用者。
- 干性AMD风险:HR 0.19(95%CI 0.14-0.26),对照为非NAC使用者。
- 湿性AMD风险:HR 0.31(95%CI 0.12-0.81),对照为非NAC使用者。
- 剂量反应关系:累积NAC剂量越高,AMD和干性AMD风险降低越明显。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: N-acetylcysteine (NAC) functions as both a direct antioxidant agent and precursor for glutathione (GSH) synthesis, both of which are implicated in the pathogenesis of age-related macular degeneration (AMD). However, whether NAC use confers protective effects against AMD remains unclear. This study aimed to investigate potential associations between NAC use and the risks of AMD development in a large cohort of the Taiwanese population. DESIGN: Retrospective cohort study. PARTICIPANTS: The study included 22 498 NAC users and 138 607 non-NAC users between 2003 and 2017 before propensity score matching (PSM). METHODS: This nationwide, population-based study leveraged data from the Taiwan National Health Insurance Research Database. Propensity score matching was applied to ensure comparability of baseline demographics and comorbidities between NAC users and nonusers. Stratified analyses by age and sex were conducted, and a cumulative defined daily dose was calculated to evaluate dose-response relationships among NAC users. Cox proportional hazards regression models were used post-PSM to estimate the hazard ratio (HR) for each outcome. MAIN OUTCOME MEASURES: Outcome measures included the HR of overall, dry, and wet AMD. RESULTS: After PSM, 5234 patients were included in each cohort: NAC users and non-NAC users. N-acetylcysteine users exhibited a significantly lower risk of AMD than nonusers did (HR, 0.19; 95% confidence interval [CI], 0.14-0.26; P < 0.001). This protective effect was observed for both dry AMD (HR, 0.19; 95% CI, 0.14-0.26) and wet AMD (HR, 0.31; 95% CI, 0.12-0.81). Stratified analyses demonstrated a reduced risk of AMD among NAC users, consistent across different age and sex groups. A dose-response relationship was identified, with higher cumulative doses of NAC associated with greater reductions in the risk of AMD and dry AMD. Sensitivity analyses for patients aged ≥60 and ≥70 years further supported the association between NAC use and reduced AMD risk, particularly for dry AMD. CONCLUSIONS: Use of NAC was associated with a significantly reduced risk of AMD, especially dry AMD. These findings support the need for further investigation into the effectiveness of NAC as a preventive treatment for AMD. FINANCIAL DISCLOSURES: The author(s) have no proprietary or commercial interest in any materials discussed in this article.
引用
- Tsai HR, Chang WC, Lee YC, et al. Oral Acetylcysteine and the Risk of Age-Related Macular Degeneration: A Retrospective Cohort Study. Ophthalmology. 2025. PMID: 41061823. doi:10.1016/j.ophtha.2025.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。